BeOne Medicines logo

BeOne Medicines

ONC | NASDAQ
Chart Builder DCF Calculator
$411.29
-$5.25 (-1.26%)
At close: Nov 16, 2026, 4:00 PM ET
$411.29
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.26%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
70.9
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #49/1021 (Top 5%)

Key Statistics

Market Data

Market Cap $46.76B
1D Range
410.87 418.35
52W Range
260.27 424.00

Valuation (TTM)

PE 6.63
PB 8.03
EV/EBITDA 29.51

Valuation (NTM)

Forward PE 47.07
Forward PEG 0.35
Price Target $420.00
Loading financial charts...

Profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial...

Sector Healthcare
Industry Biotechnology
Employees 12,000
IPO Date Feb 3, 2016
Fiscal Year January - December

Latest News

BeOne Medicines Q3 Earnings Call Highlights

11 days ago · marketbeat.com

BeOne Medicines Q3 Earnings Call Highlights
Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics

11 days ago · zacks.com

Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics
BeOne Medicines AG (ONC) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

BeOne Medicines AG (ONC) Q3 2026 Earnings Call Transcript
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

12 days ago · businesswire.com

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
U.S. FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination in First-Line Mantle Cell Lymphoma

13 days ago · businesswire.com

U.S. FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination in First-Line Mantle Cell Lymphoma
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics

14 days ago · zacks.com

Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics
New Strong Buy Stocks for November 3rd

14 days ago · zacks.com

New Strong Buy Stocks for November 3rd
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

24 days ago · businesswire.com

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

25 days ago · businesswire.com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

26 days ago · businesswire.com

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

Earnings

Latest Earnings
Nov 5, 2026
EPS
$4.59
Beat +96.15%
REV
$1.89B
Beat +7.69%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$422.50
Upside
+2.73%
Buy (10)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.